MRKR

• Completed a $56.5 million public offering of common stock to support pipeline growth. - Treated first patient with MT-401 in Phase II trial for post-transplant acute myeloid leukemia (AML), with several sites open and enrolling. - Optimizing MT-401 cell therapy manufacturing process and preparing to operationalize new in-house facility. - MT-401 well tolerated in Phase I trial with no major toxicities and demonstrated antitumor effect. - AML trial details: evaluating clinical efficacy in adjuvant and active disease settings post-allogeneic stem cell transplant, with primary objectives including relapse-free survival and complete remission rate. - Manufacturing optimizations include technical improvements like 50% reduction in manufacturing time and biological improvements for better cell phenotype and antigen specificity.

• Focus on completing treatment of patients in safety lead-in portion of AML study and enrolling in Phase II portion. - Anticipate opening approximately 20 sites for Phase II portion of AML study and treating first patient in main portion in Q3. - Plan to complete technology transfer from Baylor College of Medicine and manufacture in-house study drug for AML trial and future trials.

No detailed segment performance with revenue contributions provided in the transcript as there are no clear product segments with specified revenue breakdowns.

• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from forecasts, as described in the most recent Form 10-Q and 10-K on file with the SEC. No specific operational failures discussed in detail during the call.

Q: With regards to the safety lead-in of the six patients, when will disclosures be made and what can be expected from those six patients?

A: Primary objective is safety, looking at dose-limiting toxicities. Anticipate completing safety lead-in mid-year and potential announcement for main portion of Phase II. Safety lead-in for dose learning toxicity has been cleared safely.

Q: Is there a possibility the main portion of the Phase II could use higher doses of MT-401 than the safety lead-in?

A: The improved manufacturing process allows exploration of higher doses, with data from Phase I showing higher doses were safe and opportunity to increase dose in main portion of Phase II without additional safety readings.

Q: How do manufacturing improvements impact cost and time savings long-term and if the process can be utilized long-term?

A: Simplified manufacturing process has positive impact on cost of final drug product due to reduced cell culture time and interventions. The process has a strong basis for future commercialization and further optimization.

Q: Are there plans to expand on the collaboration with ABB regarding robotics implementation?

A: Excited about collaboration with ABB, robotic technology can improve manufacturing process consistency. Looking to continue working towards integrating robotic process in MT-401 manufacture for future commercialization.

Q: Thoughts on next potential indications based on BCM proof of concept?

A: Focused on AML, but looking at other indications in autologous program like pancreatic cancer, based on data and unmet need.

Q: Update on Baylor's AML trial and plans to present side-by-side comparisons of drug product?

A: Baylor nearly complete with last dose level in dose escalation phase, but delayed due to COVID. Plans to present side-by-side comparisons of drug product manufactured with new and old approaches at meetings like ISCT and ASGCT.

Q: Any biological data needed to feed to FDA regarding reagents in the first six patients?

A: Primarily focused on dose-limiting toxicities for safety lead-in. No additional biological data needed beyond what's already provided regarding reagent similarities, as safety lead-in is about monitoring for DLTs